{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.inluriyo:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.inluriyo%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.006163,
    "timestamp_received": "2026-05-09T05:48:15.357468+00:00Z",
    "timestamp_returned": "2026-05-09T05:48:15.363631+00:00Z",
    "trace_id": "18b7025e-a22e-490f-b9dc-4eae5e5021ea"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": "ind:ema.inluriyo:0",
      "indication": "Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER -positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen.",
      "initial_approval_date": "2026-01-09",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/inluriyo-epar-public-assessment-report_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized imlunestrant as a monotherapy for the treatment of adult patients with estrogen receptor (ER-positive), HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen. The EPAR notes that in pre- or perimenopausal women, or men, imlunestrant should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. Furthermore, it notes that patients should be selected based on the presence of an activating ESR1-variant in tumor or in plasma specimens, using a CE-marked in vitro diagnostic with the corresponding intended purpose or an alternative validated test.",
      "raw_biomarkers": "oestrogen receptor (ER -positive, HER2-negative ... with an activating ESR1-mutation",
      "raw_cancer_type": "breast cancer",
      "raw_therapeutics": "Inluriyo (imlunestrant)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.inluriyo",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Inluriyo (imlunestrant) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Eli Lilly Nederland B.V. Inluriyo (imlunestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/inluriyo-epar-product-information_en.pdf. Revised February 2026. Accessed May 5, 2026.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/inluriyo",
          "https://www.ema.europa.eu/en/documents/product-information/inluriyo-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2026-05-05",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Eli Lilly Nederland B.V.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Inluriyo",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "imlunestrant",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2026-01-23",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": "EMEA/H/C/006184",
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2026-02-23",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}